Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438067 | 0.96 | CYP3A4 (0.61) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL8198560 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7905176 | 0.86 | CYP3A4 (0.58) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL27287019 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4640173 | 0.84 | SREBF2 (0.67) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL13680751 | 0.84 | HPGDS (0.61) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL12180534 | 0.83 | RAB9A (0.59) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL266577 | 0.83 | CYP2E1 (0.65) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL7912924 | 0.81 | PTGS2 (0.56) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL18725058 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP2E1CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730946-B | 2-Phenyl-4-methylthiazole compound as well as preparation method and application thereof | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2024-11-12 | — | — | CN | claimed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| CN-116730946-A | 2-phenyl-4-methylthiazole compound as well as preparation method and application thereof | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2023-09-12 | — | — | CN | claimed |
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | claimed |
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | claimed |
| EP-2955173-A1 | NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-12-16 | — | — | EP | claimed |
| EP-2651901-B1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-05-27 | — | — | EP | claimed |
| EP-2651901-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | claimed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | claimed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| EP-1654238-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005009978-A1 | 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | CYP3A4 1381/4885CYP2E1 255/4885CYP2A6 3367/4885 |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CYP3A4 3232/4885CYP2E1 3052/4885CYP2A6 3387/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CYP3A4 4307/4885CYP2E1 4435/4885CYP2A6 3830/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CYP3A4 1782/4885CYP2E1 1176/4885CYP2A6 1062/4885 |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CYP3A4 3232/4885CYP2E1 3052/4885CYP2A6 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.